BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 2004;78:8524-35. [PMID: 15280461 DOI: 10.1128/JVI.78.16.8524-8535.2004] [Cited by in Crossref: 84] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Constantinescu I, Dinu AA, Boscaiu V, Niculescu M. Hepatitis B virus core promoter mutations in patients with chronic hepatitis B and hepatocellular carcinoma in bucharest, romania. Hepat Mon. 2014;14:e22072. [PMID: 25477976 DOI: 10.5812/hepatmon.22072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
2 O'Brien M, Casselman A, Smart G, Gretchen A, Kaita K, Kadkhoda K. Retrospective study of the prevalence and clinical significance of hepatitis B virus precore and basal core promoter variants. Can J Gastroenterol Hepatol 2015;29:e1-6. [PMID: 26401823 DOI: 10.1155/2015/940825] [Reference Citation Analysis]
3 Fan J, Wang Y, Xiong H, Guo X, Cheng YC. Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility. J Gen Virol 2014;95:2523-30. [PMID: 25028473 DOI: 10.1099/vir.0.066886-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Rodriguez-Frias F, Buti M, Tabernero D, Homs M. Quasispecies structure, cornerstone of hepatitis B virus infection: Mass sequencing approach. World J Gastroenterol 2013; 19(41): 6995-7023 [PMID: 24222943 DOI: 10.3748/wjg.v19.i41.6995] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
5 Azmi AN, Tan SS, Mohamed R. Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. World J Gastroenterol 2014; 20(34): 12045-12055 [PMID: 25232242 DOI: 10.3748/wjg.v20.i34.12045] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 Amini-Bavil-Olyaee S, Vucur M, Luedde T, Trautwein C, Tacke F. Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains. J Virol. 2010;84:1026-1033. [PMID: 19889778 DOI: 10.1128/jvi.01796-09] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
7 Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T, Kang Y, Tabernero D, Yagmur E, Rodríguez-Frías F, Gregori J, Luedde T, Trautwein C, Ploss A, Tacke F. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol 2017;67:246-54. [PMID: 28392234 DOI: 10.1016/j.jhep.2017.03.027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
8 Pondé RA. Atypical serological profiles in hepatitis B virus infection. Eur J Clin Microbiol Infect Dis 2013;32:461-76. [PMID: 23192489 DOI: 10.1007/s10096-012-1781-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
9 Park YM. Clinical utility of complex mutations in the core promoter and proximal precore regions of the hepatitis B virus genome. World J Hepatol 2015; 7(1): 113-120 [PMID: 25625002 DOI: 10.4254/wjh.v7.i1.113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Cortes-Mancera F, Loureiro CL, Hoyos S, Restrepo JC, Correa G, Jaramillo S, Norder H, Pujol FH, Navas MC. Etiology and Viral Genotype in Patients with End-Stage Liver Diseases admitted to a Hepatology Unit in Colombia. Hepat Res Treat. 2011;2011:363205. [PMID: 21941645 DOI: 10.1155/2011/363205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
11 Liu H, Wan Z, She L, Zhu Y, Cai Z, Wu B, Zhuang Q, Ke P, Wu X, Li Z, Huang X. Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus. Front Pharmacol 2021;12:648170. [PMID: 33935748 DOI: 10.3389/fphar.2021.648170] [Reference Citation Analysis]
12 Li Y, Ito M, Sun S, Chida T, Nakashima K, Suzuki T. LUC7L3/CROP inhibits replication of hepatitis B virus via suppressing enhancer II/basal core promoter activity. Sci Rep 2016;6:36741. [PMID: 27857158 DOI: 10.1038/srep36741] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
13 Baumert TF, Thimme R, Weizsäcker FV. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 82-90 [PMID: 17206757 DOI: 10.3748/wjg.v13.i1.82] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 79] [Article Influence: 6.4] [Reference Citation Analysis]
14 Zhang D, Ma S, Zhang X, Zhao H, Ding H, Zeng C. Prevalent HBV point mutations and mutation combinations at BCP/preC region and their association with liver disease progression. BMC Infect Dis. 2010;10:271. [PMID: 20846420 DOI: 10.1186/1471-2334-10-271] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
15 de Almeida Pondé RA. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol Biol Rep 2021;48:843-54. [PMID: 33296069 DOI: 10.1007/s11033-020-06056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yildiz UH, Inci F, Wang S, Toy M, Tekin HC, Javaid A, Lau DT, Demirci U. Recent advances in micro/nanotechnologies for global control of hepatitis B infection. Biotechnol Adv 2015;33:178-90. [PMID: 25450190 DOI: 10.1016/j.biotechadv.2014.11.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
17 Tacke F, Kroy DC. Treatment for hepatitis B in patients with drug resistance. Ann Transl Med 2016;4:334. [PMID: 27761438 DOI: 10.21037/atm.2016.09.19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
18 Tuteja A, Siddiqui AB, Madan K, Goyal R, Shalimar V, Kaur N, Panda SK, Narayanasamy K, Subodh S, Acharya SK. Mutation profiling of the hepatitis B virus strains circulating in North Indian population. PLoS One. 2014;9:e91150. [PMID: 24637457 DOI: 10.1371/journal.pone.0091150] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
19 Belyhun Y, Liebert UG, Maier M. Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia. PLoS One 2018;13:e0191970. [PMID: 29408943 DOI: 10.1371/journal.pone.0191970] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Tacke F, Shirvani-Dastgerdi E. Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro. Hepat Mon 2012;12:357-60. [PMID: 22879823 DOI: 10.5812/hepatmon.6131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
21 Croagh CM, Desmond PV, Bell SJ. Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance. World J Hepatol 2015; 7(3): 289-303 [PMID: 25848459 DOI: 10.4254/wjh.v7.i3.289] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 11.5] [Reference Citation Analysis]
22 Tacke F, Liedtke C, Bocklage S, Manns MP, Trautwein C. CREB/PKA sensitive signalling pathways activate and maintain expression levels of the hepatitis B virus pre-S2/S promoter. Gut 2005;54:1309-17. [PMID: 15871998 DOI: 10.1136/gut.2005.065086] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
23 Homs M, Buti M, Quer J, Jardí R, Schaper M, Tabernero D, Ortega I, Sanchez A, Esteban R, Rodriguez-Frias F. Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genome. Nucleic Acids Res 2011;39:8457-71. [PMID: 21742757 DOI: 10.1093/nar/gkr451] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
24 陆德云, 王甦, 赵连三. 影响拉米夫定相关乙肝病毒YMDD变异的因素. 世界华人消化杂志 2005; 13(18): 2243-2245 [DOI: 10.11569/wcjd.v13.i18.2243] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Di Bisceglie AM, King WC, Lisker-Melman M, Khalili M, Belle SH, Feld JJ, Ghany MG, Janssen HLA, Lau D, Lee WM, Ling SC, Cooper S, Rosenthal P, Schwarz KB, Sterling RK, Teckman JH, Terrault N; Hepatitis B Research Network (HBRN). Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. J Viral Hepat 2019;26:856-65. [PMID: 30974509 DOI: 10.1111/jvh.13104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
26 Malik A, Singhal DK, Albanyan A, Husain SA, Kar P. Hepatitis B virus gene mutations in liver diseases: a report from New Delhi. PLoS One. 2012;7:e39028. [PMID: 22720023 DOI: 10.1371/journal.pone.0039028] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
27 Malmström S, Larsson SB, Hannoun C, Lindh M. Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load--down-regulated transcription of PgRNA has limited impact. PLoS One. 2012;7:e36349. [PMID: 22911677 DOI: 10.1371/journal.pone.0036349] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
28 Lindh M, Hannoun C, Malmström S, Lindberg J, Norkrans G. Lamivudine resistance of hepatitis B virus masked by coemergence of mutations in probe region of the COBAS AMPLICOR assay. J Clin Microbiol 2006;44:2587-9. [PMID: 16825388 DOI: 10.1128/JCM.00265-06] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
29 Shirvani-Dastgerdi E, Tacke F. Molecular interactions between hepatitis B virus and delta virus. World J Virology 2015; 4(2): 36-41 [PMID: 25964870 DOI: 10.5501/wjv.v4.i2.36] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
30 Chen YL, Mo YQ, Zheng DH, Ma JD, Jing J, Dai L. Patients with Coexistence of Circulating Hepatitis B Surface Antigen and Its Antibody May Have a Strong Predisposition to Virus Reactivation During Immunosuppressive Therapy: A Hypothesis. Med Sci Monit 2017;23:5980-5. [PMID: 29248936 DOI: 10.12659/msm.905033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]